Discover OncoCyte's Q4 2024 progress with its cutting-edge kidney transplant test. Insights on FDA ambitions, market strategies & financial runway.

Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, ...

The recent NHANES III United States survey of ~17,000 subjects without apparent thyroid disease, reported detectable TPOAb levels in 12 % of subjects using a competitive immunoassay method.

A major biotech breakthrough is happening in New Orleans. Beken Bio, a biotech startup company that is soon to be based at ...

MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces the Company’s consolidated financial results for the year ended December 31, 2024. For details of the audited ...

The global therapeutic drug monitoring market is poised for significant expansion, with projections indicating a rise from USD 1,203.9 million in 2024 to an impressive USD 2,527.9 million by 2034.

Certified Packaging within the Food and Beverage Industry Asia-Pacific PFAS Testing Market Asia-Pacific PFAS Testing Market ...

Idexx's financial health is strong. The firm had historically funded its expansions and acquisitions primarily through its own cash generation and held virtually no long-term debt until 2014. Unlike ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

The CRISLA-3G laser isotope separation technology was evaluated and determined to meet all elements required for TRL-4, ...

MAG Silver Corp. (TSX / NYSE American: MAG) ("MAG", or the "Company") announces the Company's consolidated financial results for the year ...